Pentoxifylline and Contrast Induced Nephropathy
Not Applicable
Completed
- Conditions
- Contrast Induced Nephropathy.Acute renal failure (includes acute renal impairment)
- Registration Number
- IRCT201011135161N1
- Lead Sponsor
- Vice-chancellor for Research Affairs, Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 199
Inclusion Criteria
Eligibility was defined as the age between 18 and 65 years and baseline serum creatinine=1.5 mg/dl. Exclusion criteria were acute myocardial infarction, congestive heart failure, hemodynamic instability during or after procedure, known allergy or previous administration of pentoxifylline and use of concomitant nephrotoxic agents and diuretics.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum creatinine. Timepoint: 24 hours before intervention and 48 hours after PCI. Method of measurement: Blood test.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pentoxifylline's protective effects against contrast-induced nephropathy?
How does pentoxifylline compare to standard-of-care treatments for preventing acute renal failure in patients undergoing contrast imaging?
Are there specific biomarkers that identify patients most likely to benefit from pentoxifylline in contrast-induced nephropathy prevention?
What are the known adverse events associated with pentoxifylline use in renal protection and how are they managed?
What combination therapies or alternative drugs show promise in preventing contrast-induced nephropathy alongside pentoxifylline?